B Cell News and Research

RSS

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.

26 Mar 2015

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.

26 Mar 2015

Metabolic imbalance can trigger respiratory diseases in early childhood

An imbalance in our metabolism can trigger inflammatory processes in the body and activate the immune system. In a recent study, published in the Journal of Allergy and Clinical Immunology, UFZ researchers have been able to show that this applies even to newborns and children under one year of age, and is correlated with the development of respiratory diseases in early childhood.

26 Mar 2015

Patients with sickle cell disease have sleep disordered breathing problem

A new study in the Journal of Clinical Sleep Medicine revealed that 44 percent of adults with sickle cell disease who report trouble sleeping actually have a clinical diagnosis of sleep disordered breathing, including sleep apnea, which lowers their oxygen levels at night.

26 Mar 2015

UVA researchers develop compound that could lead to improved leukemia treatments

Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved treatments in people. The researchers call it an exciting "new paradigm" for treating leukemia.

26 Mar 2015

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience.

26 Mar 2015

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state--may better model the genetic contributions to each patient's particular disease. In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer.

26 Mar 2015

AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

26 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Stem cells can generate any type of cell in the body, but they are inactive most of the time—and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations. In the case of blood stem cells (also called hematopoietic stem cells or HSCs), this can lead to blood cancers, a loss of blood cells and an impaired ability to fight disease.

26 Mar 2015

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests.

25 Mar 2015

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology.

25 Mar 2015

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development.

25 Mar 2015

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Patients with metastatic renal cell carcinoma reported a marked improvement in their health-related quality of life when given sunitinib on a 2 weeks on and 1 week off schedule compared with a 4 weeks on and 2 weeks off regimen, a Japanese study finds.

25 Mar 2015

B Cell News and Research

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

Metabolic imbalance can trigger respiratory diseases in early childhood

Patients with sickle cell disease have sleep disordered breathing problem

UVA researchers develop compound that could lead to improved leukemia treatments

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

AstraZeneca, HSCI collaborate to find new treatments for diabetes

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Limited anticancer role for preoperative statins in localised RCC setting

IMDC prognostic model valid in second-line RCC therapy

Alternating sunitinib, everolimus not supported in advanced RCC

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

National Science Foundation announces recipient of Faculty Early Career Development Award

Using single B cell screening to boost antibody discovery eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News